Latest news with #MichaelMorrissey
CBS News
07-07-2025
- CBS News
Sgt. Yuri Bukhenik, key investigator in Karen Read case, transferred by Massachusetts State Police
Sgt. Yuri Bukhenik, a key investigator in the Karen Read case, has been transferred to another Massachusetts State Police division just weeks after the high-profile trial ended. Bukhenik, who previously worked with Norfolk County District Attorney Michael Morrissey's office, has been reassigned to an administrative role for the Division of Field Services in the South Boston barracks, State Police spokesperson Tim McGuirk said. "As a Sergeant assigned to the DST Commander's Office, Sergeant Bukhenik will perform a variety of administrative functions in support of the Division's daily operations," McGuirk said in a statement. Read was acquitted of murder and manslaughter charges on June 18. Bukhenik testified in both Read's first and second trials. After the first trial, Bukhenik forfeited five vacation days following an internal affairs investigation. The investigation found that Bukhenik should have reprimanded and reported former State Police Trooper Michael Proctor for sending inappropriate text messages about Read to a group chat that included Bukhenik. Bukhenik read Proctor's text messages aloud in court during the second trial. In the texts, Proctor referred to Read as a "whackjob [expletive]" and said in one message that "hopefully she kills herself." Bukhenik testified that he did not respond with words to Proctor's messages, but acknowledged one with a "thumbs up" emoji. State police are currently accepting applications for Bukhenik's former position with Norfolk County. "As the Colonel said following the conclusion of the second trial, the events of the last three years have challenged our Department to thoroughly review our actions and take concrete steps to deliver advanced investigative training, ensure appropriate oversight, and enhance accountability," McGuirk said in the statement. "Our focus remains on delivering excellent police services that reflect the value of professionalism and maintaining public trust."
Business Wire
30-06-2025
- Business
- Business Wire
Inverness Graham-Backed Alliant Acquires AnalyticsIQ, Expanding Suite of People-Based Marketing Data & Analytics Solutions
WAYNE, Pa.--(BUSINESS WIRE)--Inverness Graham, a Philadelphia-based buyout firm focused on acquiring innovative companies where technology is transforming traditional industry, announced today that its marketing data and analytics company, Alliant, has acquired AnalyticsIQ. An innovator in predictive analytics and people-based marketing data, AnalyticsIQ blends cognitive psychology with statistical analysis to enhance behavioral targeting and drive marketing performance. The company utilizes survey-based methodology and machine learning to model consumer behavior and intent, enabling advertisers to reach high-value audiences and enhance campaign outcomes through more effective targeting and personalization. The acquisition of AnalyticsIQ strengthens the combined company's market position and establishes it as a top-tier provider of comprehensive data-driven marketing solutions. 'AnalyticsIQ's innovative data solutions strongly complement Alliant's strengths in cooperative data and analytics,' said Michael Morrissey, Managing Principal at Inverness Graham. 'Combining Alliant's proprietary transaction data with AnalyticsIQ's predictive modeling and digital integrations enhances our collective ability to deliver high-performing, insight-driven audiences across both traditional and emerging marketing channels. Together, the combined business enables a differentiated, data-rich platform with more customer applications and deeper market reach. We look forward to supporting Alliant and AnalyticsIQ's next phase of growth together.' As part of the acquisition, Scarlett Shipp, the current Chief Executive Officer ('CEO') of AnalyticsIQ, has been appointed the new CEO of the combined business. JoAnne Monfradi Dunn, Alliant's founder and CEO, has announced her retirement from day-to-day operations and will assume an active Board seat to guide the transition and continue providing strategic leadership at the Board level. 'Our team has spent years building predictive data that helps brands not just understand what people do—but why they do it,' said Scarlett Shipp. 'Joining forces with Alliant enables us to scale that mission and bring even more powerful insights to clients across channels. Together, we're building on our industry leadership to create a data company that raises the bar—delivering an unprecedented combination of differentiated data, trust, and results.' Inverness Graham and Alliant are actively seeking further acquisitions and strategic partnerships with innovative companies that provide high-quality marketing data, analytics and technology. Faegre Drinker Biddle & Reath LLP served as legal counsel to Inverness Graham. Stephens Inc. served as exclusive financial advisor to AnalyticsIQ. Terms of the transaction were not disclosed. About Inverness Graham Investments Inverness Graham is a Philadelphia based firm focused on acquiring innovative companies where technology is transforming traditional industry. The firm's Flagship strategy focuses on high-growth businesses in Healthcare, Tech-Enabled Services / Software and Advanced Manufacturing. The firm's Green Light strategy targets tech-enabled businesses where Environmental Sustainability is a key driver of accelerating growth. Inverness Graham executes a differentiated, repeatable model for value creation through its proprietary Strategic Platform Build approach. Founded by senior executives of the Graham Group, the firm builds upon a 60-year legacy of operational excellence, bringing substantial value creation resources and an innovative mindset to support its portfolio company partners.
CBS News
25-06-2025
- Politics
- CBS News
Karen Read attorney Alan Jackson fires back at Hank Brennan for comments on jury's verdict
Karen Read's lead attorney, Alan Jackson, has accused special prosecutor Hank Brennan of ethical violations for attacking the jury's verdict. Read was found not guilty of second-degree murder and manslaughter last week in the 2022 death of her boyfriend, Boston police officer John O'Keefe. Brennan waited five days to comment on the verdict. In a statement Monday, he said he was disappointed with it and that there was "only one person" responsible for O'Keefe's death. Brennan also condemned "witness abuse" in the case. Jackson fired back Tuesday with a long response, saying Brennan, "in an egregious breach of prosecutorial ethics, has tried to publicly shame and discredit that very jury." "For him to attempt to supplant his personal views for that of the jury is a desperate attempt to save face in the wake of a unanimous rejection of the prosecution's case," Jackson said in a statement. "The only job of an ethical prosecutor is to seek the truth in a just and fair manner. The Commonwealth fell wildly short of that responsibility. Theirs was not an effort to find justice for John O'Keefe. Rather, it was a personal vendetta against Karen Read by DA Michael Morrissey and his hand-picked prosecutors-and it cost the people of Norfolk County millions." Morrissey has said very little about the verdict. In a brief statement to WBZ-TV he would only say "The jury has spoken." Read is now facing a civil wrongful death lawsuit that was filed by O'Keefe's family in Plymouth Superior Court in August 2024.
CBS News
19-06-2025
- CBS News
Norfolk District Attorney Michael Morrissey reacts to Karen Read verdict, "The jury has spoken"
The latest on the Karen Read verdict as the town of Canton looks to move on The latest on the Karen Read verdict as the town of Canton looks to move on The latest on the Karen Read verdict as the town of Canton looks to move on Norfolk District Attorney Michael Morrissey issued a brief statement Thursday to WBZ-TV, his first comment since the verdict in the high-profile Karen Read trial. Nearly 24 hours after a jury of 12 men and women acquitted Read of murder and other charges related to the death of Boston police officer John O'Keefe, Morrissey addressed the unsuccessful prosecution of the case for the first time. "The jury has spoken," Morrissey told WBZ-TV. Read was only found guilty of operating under the influence of alcohol (OUI). WBZ-TV had reached out to Morrissey and the DA's office five times since the verdict was handed down just before 3 p.m. on Wednesday, by email and attempting to reach him in person, but had not heard back until just before 2 p.m. on Thursday. Special prosecutor Hank Brennan did not comment about the verdict when he left Norfolk Superior Court in Dedham on Wednesday. In 2023, Morrissey released a video statement regarding Read's case. In the statement, which came before Read's first trial, the district attorney called for the end of "absolutely baseless" harassment of witnesses in the case. "Conspiracy theories are not evidence," Morrissey said. "The idea that multiple police departments, EMTs, Fire personnel, the medical examiner, and the prosecuting agency are joined in, or taken-in by, a vast conspiracy should be seen for what it is - completely contrary to the evidence and a desperate attempt to re-assign guilt." Adam Lally prosecuted Read's first trial for the Norfolk DA's office. The trial ended in a mistrial due to hung jury. Brennan was hired as the special prosecutor in the retrial, funded by taxpayer dollars.
Yahoo
07-06-2025
- Business
- Yahoo
BofA Hikes Exelixis, Inc. (EXEL) Target Amid CRC Caution
On Thursday, analysts at BofA Securities raised the price target for Exelixis, Inc. (NASDAQ:EXEL) to $46 from $45, with a Neutral rating. This minor change in the price target, reflecting an upside of nearly 8% from the current stock price, signals the company's revised evaluation of the Zanza pipeline asset. The company is all set to begin the STELLAR-311 trial of Zanza in NET, aiming for as many as three new INDs within this year. During the latest earnings call, the management expressed optimism around its Zanza pipeline asset. As the CEO of Exelixis, Inc. (NASDAQ:EXEL), Michael Morrissey, mentioned: "We're excited to advance Zanza to the center stage in 2025 as our next oncology franchise opportunity." White medicinal tablets. Photo by The analysts noted the significance of the upcoming readouts for the Zanza asset, renal cell carcinoma (RCC), and colorectal cancer (CRC). Despite the excitement for Zanza, analysts remain cautious about the prospects of the CRC population, which is considered the most critical. They substantially discount its chances of success here, citing that the recent updates to the statistical analysis cast a shadow over the stock's potential. Without a breakthrough in the CRC intent-to-treat group, analysts believe that Zanza's peak sales will be between $500 million and $1 billion in the years ahead. Exelixis, Inc. (NASDAQ:EXEL) is a California-based biopharmaceutical company that discovers, develops, and markets new cancer solutions. With a focus on oncology, the company has a leading network of drug development, clinical trials, and commercialization of drugs for difficult-to-treat cancer types. While we acknowledge the potential of EXEL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure. None.
